Heart safety check for hepatitis b drug candidate

NCT ID NCT06422767

Completed Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study investigates whether a single dose of bepirovirsen, a potential treatment for hepatitis B, affects the heart's electrical activity. Healthy adults aged 18 to 55 receive either the drug or a placebo, and their heart rhythms are monitored continuously by ECG. The goal is to see if bepirovirsen causes any changes in the QT interval, a measure linked to heart rhythm safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bepirovirsen
What this could lead to: If the drug shows no heart-rhythm effects, it may support further development of bepirovirsen as a treatment for hepatitis B.
What could go wrong: This is an early-phase safety study in healthy people, not patients. The drug could still cause heart issues or fail in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Austin, Texas, 78744 -1645, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.